Merck delivered a strong result with meaningful revenue growth in the second quarter, driven by strong underlying demand for products across their growth pillars and the continued recovery of the business due to improved patient access. Its Human Health business continues to regain momentum and achieved 18% growth in Q2 excluding the impact of foreign exchange. The company’s sales of its core Keytruda drug increased by 20% to $4.2 billion in oncology, reflecting continued strong global demand. I ....
20 Sep 2021
Merck & Co., Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 9/21
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Merck & Co., Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 9/21
- Published:
20 Sep 2021 -
Author:
Ishan Majumdar -
Pages:
14
Merck delivered a strong result with meaningful revenue growth in the second quarter, driven by strong underlying demand for products across their growth pillars and the continued recovery of the business due to improved patient access. Its Human Health business continues to regain momentum and achieved 18% growth in Q2 excluding the impact of foreign exchange. The company’s sales of its core Keytruda drug increased by 20% to $4.2 billion in oncology, reflecting continued strong global demand. I ....